Abstract:The major targets of current drugs used in mental health, such as neurotransmitter receptors and transporters, are based on serendipitous findings from several decades ago, and there is currently a severe drought of new drug targets. There is a pressing need for novel drugs, and much hope has been placed on the use of molecular genetics to help define them. However, despite evidence for a genetic basis to schizophrenia stretching back for over a century, and a heritability of about 80%, the identification of susceptibility genes has been an uphill struggle. Candidate gene studies, which have generally focussed on obvious candidates from the dopamine and serotonin systems, as well as genes involved in brain development, have not generally been successful, although meta-analysis indicates that the dopamine D3 receptor gene (DRD3) and the serotonin receptor gene type 2A (HTR2A) may have a very small influence on risk. Linkage analysis has provided robust evidence of genetic loci, for example, on chromosomes 8p, 13q and 22q, and also implies shared genetic aetiology with bipolar disorder. The identification of these loci together with advances in genetic technology, especially the characterisation of polymorphisms, the understanding of haplotypes and the development of statistical methods, has lead to the identification of several plausible susceptibility genes, including neuregulin 1, proline dehydrogenase and dysbindin. Interestingly, these genes point more towards a role for the glutamate pathway rather than the dopamine pathway in schizophrenia. We have attempted to replicate some of these findings in schizophrenic patients from SW China, and we find significant association with a novel neuregulin 1 haplotype, with proline dehydrogenase polymorphisms, but not with catechol-O-methyltransferase (COMT). The replication of neuregulin 1 association on chromosome 8p by several investigators is the most convincing to date, and the presence of a syndrome similar to dementia praecox of 8p linked families, and the lack of linkage of bipolar disorder to this region is a testament to the ideas of Kraepelin more than 100 years ago.

An alternative splicing hypothesis for neuropathology of schizophrenia: evidence from studies on historical candidate genes and multi-omics data

Transcriptomic analysis of postmortem brain identifies dysregulated splicing events in novel candidate genes for schizophrenia.

Significant Linkage and Association Between a Functional (gt)n Polymorphism in Promoter of the N-methyl-D-aspartate Receptor Subunit Gene (GRIN2A) and Schizophrenia.

Single molecule in situ hybridization reveals distinct localizations of schizophrenia risk-related transcripts SNX19 and AS3MT in human brain

The genetics of schizophrenia: glutamate not dopamine?

A Splicing-Regulatory Polymorphism in Drd2 Disrupts Zranb2 Binding, Impairs Cognitive Functioning and Increases Risk for Schizophrenia in Six Han Chinese Samples

Long-read sequencing reveals the RNA isoform repertoire of neuropsychiatric risk genes in human brain

Polygenic risk for schizophrenia converges on alternative polyadenylation as molecular mechanism underlying synaptic impairment

Genetic Diversity in Schizophrenia: Developmental Implications of Ultra-Rare, Protein-Truncating Mutations

A functional schizophrenia-associated genetic variant near the TSNARE1 and ADGRB1 genes

Brain transcriptional regulatory architecture and schizophrenia etiology converge between East Asian and European ancestral populations

Alternative Splicing As a Biomarker and Potential Target for Drug Discovery

Multiple Rare Risk Coding Variants in Postsynaptic Density-Related Genes Associated With Schizophrenia Susceptibility

Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis

Analysis of the caudate nucleus transcriptome in individuals with schizophrenia highlights effects of antipsychotics and new risk genes

Mendelian Randomization Study Using Dopaminergic Neuron-Specific eQTL Identifies Novel Risk Genes for Schizophrenia

Effect of schizophrenia risk gene polymorphisms on cognitive and neural plasticity

Genetic architecture of RNA editing, splicing and gene expression in schizophrenia

Associating Multimodal Neuroimaging Abnormalities with the Transcriptome and Neurotransmitter Signatures in Schizophrenia.

Mechanisms of Neuronal Alternative Splicing and Strategies for Therapeutic Interventions

Synergistic effects of common schizophrenia risk variants